Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x

MEDEXUS Aktie

>MEDEXUS Performance
1 Woche: +5,4%
1 Monat: +20,2%
3 Monate: +13,3%
6 Monate: +30,7%
1 Jahr: +27,3%
laufendes Jahr: +13,3%
>MEDEXUS Aktie
Name:  MEDEXUS PHARMACEUTIC.
Land:  Kanada
Sektor:  Gesundheit
ISIN/ Wkn:  CA58410Q2036 / A2PA3U
Symbol/ Ticker:  P731 (Frankfurt)
Kürzel:  FRA:P731, ETR:P731, P731:GR
Index:  -
Webseite:  https://www.medexus.com/
Profil:  Medexus Pharmaceuticals Inc. is a North American specialty pharmaceutical company that primarily focuses on providing innovative and niche products within the realms of hematology, autoimmune diseases, and allergy markets. Its portfolio includes both..
>Volltext..
Marktkapitalisierung:  69.87 Mio. EUR
Unternehmenswert:  78.84 Mio. EUR
Umsatz:  87.68 Mio. EUR
EBITDA:  11.23 Mio. EUR
Nettogewinn:  -0.25 Mio. EUR
Gewinn je Aktie:  -0.01 EUR
Schulden:  21.92 Mio. EUR
Liquide Mittel:  12.95 Mio. EUR
Operativer Cashflow:  13.18 Mio. EUR
Bargeldquote:  0.24
Umsatzwachstum:  -3%
Gewinnwachstum:  -108.61%
Dividende je Aktie:  -
Dividendenrendite:  -
Dividendenschätzung:  -
Insiderhandel:  -
Suchwörter:  MEDEXUS
Letzte Datenerhebung:  05.04.26
>MEDEXUS Kennzahlen
Aktien/ Unternehmen:
Aktien: 32.3 Mio. St.
Frei handelbar: 91.82%
Leerverk. Aktien: -
Rückkaufquote: -23.77%
Mitarbeiter: 91
Umsatz/Mitarb.: 1 Mio. EUR
Analysten:
Analystenrating: Strong buy
Kursziel: 103.46%
Bewertung:
KGV: -
KGV lG: 998.8
KUV: 0.77
KBV: 1.55
PEG-Ratio: -
EV/EBITDA: 7.02
Rentabilität:
Bruttomarge: 52.72%
Gewinnmarge: -0.29%
Operative Marge: 3.03%
Managementeffizenz:
Gesamtkaprendite: -0.19%
Eigenkaprendite: -0.67%
>MEDEXUS Peer Group
Gesundheit, Autoimmunerkrankungen
 
12.02.26 - 15:01
 Medexus Pharmaceuticals: Umsatzrückgang in Q3 2026 durch Wettbewerbsdruck (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
11.02.26 - 23:51
 Medexus Pharmaceuticals reports Q3 results (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
11.02.26 - 23:48
 Medexus Pharmaceuticals Inc.: Medexus Announces Fiscal Q3 2026 Results, Driven by Continued Strong Year-To-Date Product-Level Performance of GRAFAPEX (treosulfan) for Injection (Newsfile)
 
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - February 11, 2026) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today announced its operating and financial results and provided a ......
03.02.26 - 23:48
 Medexus Pharmaceuticals Inc.: Medexus Schedules Third Fiscal Quarter 2026 Conference Call (Newsfile)
 
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - February 3, 2026) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Thursday,......
20.11.25 - 13:42
 Medexus Pharmaceuticals Inc.: Medexus Announces Normal Course Issuer Bid, or NCIB, for Its Common Shares (Newsfile)
 
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - November 20, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to announce that the Toronto Stock Exchange has accepted......
17.11.25 - 14:42
 Medexus Pharmaceuticals Inc.: Medexus Announces US$51.0 million in New Credit Facilities and Intention to Commence Normal Course Issuer Bid, or NCIB, for its Common Shares (Newsfile)
 
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - November 17, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today entered into a new senior secured credit agreement with Natio......
13.11.25 - 17:18
 Medexus Pharmaceuticals reports FQ2 results (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
13.11.25 - 15:18
 Medexus Pharmaceuticals: Umsatz im zweiten Quartal leicht rückläufig, Marge verbessert sich (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
13.11.25 - 00:18
 Medexus Pharmaceuticals Inc.: Medexus Announces Fiscal Q2 2026 Results, Driven by Strong Year-To-Date Product-Level Performance of GRAFAPEX (treosulfan) for Injection (Newsfile)
 
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - November 12, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today announced its operating and financial results and provided a ......
04.11.25 - 23:42
 Medexus Pharmaceuticals Inc.: Medexus Schedules Second Fiscal Quarter 2026 Conference Call (Newsfile)
 
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - November 4, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Thursday,......
25.09.25 - 23:42
 Medexus Pharmaceuticals Inc.: Medexus Holds Annual Meeting of Shareholders and Announces Election of Directors (Newsfile)
 
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - September 25, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today held its virtual annual meeting of shareholders. Medexus sha......
13.08.25 - 15:09
 Medexus Pharmaceuticals reports Q1 results (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
12.08.25 - 23:42
 Medexus Pharmaceuticals Inc.: Medexus Announces Fiscal Q1 2026 Results, Including Positive Results from US Launch of GRAFAPEX (treosulfan) for Injection (Newsfile)
 
Fiscal Q1 2026 net revenue of $24.6 million, net income of $0.5 million, operating income of $0.9 million, and Adjusted EBITDA* of $3.4 million$3.0 million of product-level net revenue from GRAFAP......
05.08.25 - 23:42
 Medexus Pharmaceuticals Inc.: Medexus Schedules First Fiscal Quarter 2026 Conference Call (Newsfile)
 
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - August 5, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Wednesday, ......
05.08.25 - 13:06
 Medexus Pharmaceuticals Inc.: GRAFAPEX (treosulfan) for Injection Receives CMS Approval of New Technology Add-On Payment (NTAP) for Eligible Cases in CMS′s Fiscal Year 2026 (Newsfile)
 
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - August 5, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to announce that the US Centers for Medicare & Medicaid Ser......
26.06.25 - 00:30
 Medexus Pharmaceuticals Inc.: Medexus Announces Strong Fiscal Year 2025 Results, Including Initial Results from Launch of GRAFAPEX (treosulfan) for Injection in the United States (Newsfile)
 
Fiscal year 2025 revenue of $108.3 million, record net income of $2.2 million, operating income of $8.2 million, and record Adjusted EBITDA* of $20.2 millionUS commercial launch of GRAFAPEX execut......
17.06.25 - 23:06
 Medexus Pharmaceuticals Inc.: Medexus Schedules Fourth Fiscal Quarter and Fiscal Year 2025 Conference Call (Newsfile)
 
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - June 17, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Thursday, Ju......
17.04.25 - 13:06
 Medexus Pharmaceuticals Inc.: Medexus Successfully Completes Agreement for Public Reimbursement of Trecondyv (treosulfan for injection) in Quebec, Canada (Newsfile)
 
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - April 17, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) recently completed a listing agreement with the provincial government ......
07.04.25 - 13:12
 Medexus Pharmaceuticals Inc.: Medexus Provides Update on Progress of Commercialization of GRAFAPEX (treosulfan) for Injection (Newsfile)
 
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - April 7, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to provide a business update on the progress of the commerci......
14.03.25 - 12:06
 Medexus Pharmaceuticals Inc.: Medexus Completes Agreement to Return US Commercialization Rights for Gleolan to NX Development Corp. (Newsfile)
 
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - March 14, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) recently completed an agreement with NX Development Corp., the licenso......
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Notwendigkeit ist bei weitem stärker als die Kunst. - Aischylos
>Aktien | >Anleihen | >ETFs | >Fonds | >Branchen | >Länder | >Themen | >Redaktionen
Partner:    >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!